Dexiang Chen

Summary

Affiliation: Program for Appropriate Technology in Health
Country: USA

Publications

  1. ncbi Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method
    D Chen
    PATH, Seattle, WA 98121, USA
    Vaccine 28:5093-9. 2010
  2. ncbi Opportunities and challenges of developing thermostable vaccines
    Dexiang Chen
    PATH, Seattle, WA 98107, USA
    Expert Rev Vaccines 8:547-57. 2009
  3. ncbi Characterization of the freeze sensitivity of a hepatitis B vaccine
    Dexiang Chen
    PATH, Seattle, Washington, USA
    Hum Vaccin 5:26-32. 2009
  4. ncbi Vaccine stabilization: research, commercialization, and potential impact
    Debra Kristensen
    PATH, Seattle, WA, United States
    Vaccine 29:7122-4. 2011
  5. ncbi An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model
    Melissa S Burger
    PowderJect Vaccines, Inc, Seattle, WA, USA
    J Allergy Clin Immunol 114:1301-8. 2004

Collaborators

  • Debra Kristensen
  • Melissa S Burger
  • Qili Chu
  • Lendon G Payne
  • Cindy L Zuleger
  • Xiaoyan Gao

Detail Information

Publications5

  1. ncbi Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method
    D Chen
    PATH, Seattle, WA 98121, USA
    Vaccine 28:5093-9. 2010
    ..This study demonstrates the feasibility of producing thermostable vaccines with advanced processing and formulation technologies...
  2. ncbi Opportunities and challenges of developing thermostable vaccines
    Dexiang Chen
    PATH, Seattle, WA 98107, USA
    Expert Rev Vaccines 8:547-57. 2009
    ..The challenges associated with the implementation of these novel formulations are discussed, as well as the potential benefits and opportunities of taking vaccines out of the cold chain...
  3. ncbi Characterization of the freeze sensitivity of a hepatitis B vaccine
    Dexiang Chen
    PATH, Seattle, Washington, USA
    Hum Vaccin 5:26-32. 2009
    ....
  4. ncbi Vaccine stabilization: research, commercialization, and potential impact
    Debra Kristensen
    PATH, Seattle, WA, United States
    Vaccine 29:7122-4. 2011
    ..Public sector agencies can incentivize vaccine developers to prioritize stabilization efforts through advocacy and by implementing policies that increase demand for thermostable vaccines...
  5. ncbi An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model
    Melissa S Burger
    PowderJect Vaccines, Inc, Seattle, WA, USA
    J Allergy Clin Immunol 114:1301-8. 2004
    ..CONCLUSION: This finding argues against the approach of boosting an allergen-dependent T(H)1 response and favors induction of an antigen-independent T(H)1 response for allergy immunotherapy...